Blockade of CD73 delays glioblastoma growth by modulating the immune environment
- 1 September 2020
- journal article
- research article
- Published by Springer Nature in Cancer Immunology, Immunotherapy
- Vol. 69 (9), 1801-1812
- https://doi.org/10.1007/s00262-020-02569-w
Abstract
Immunotherapy as an approach for cancer treatment is clinically promising. CD73, which is the enzyme that produces extracellular adenosine, favors cancer progression and protects the tumor from immune surveillance. While CD73 has recently been demonstrated to be a potential target for glioma treatment, its role in regulating the inflammatory tumor microenvironment has not yet been investigated. Thus, this study explores the immunotherapeutic value of the CD73 blockade in glioblastoma. The immuno-therapeutic value of the CD73 blockade was evaluated in vivo in immunocompetent pre-clinical glioblastoma model. As such, glioblastoma-bearing rats were nasally treated for 15 days with a siRNA CD73-loaded cationic-nanoemulsion (NE-siRNA CD73R). Apoptosis was determined by flow cytometry using Annexin-V staining and cell proliferation was analyzed by Ki67 expression by immunohistochemistry. The frequencies of the CD4(+), CD8(+), and CD4(+)CD25(high)CD39(+) (Treg) T lymphocytes; CD11b(+)CD45(high) macrophages; CD11b(+)CD45(low)-microglia; and CD206(+)-M2-like phenotypes, along with expression levels of CD39 and CD73 in tumor and tumor-associated immune cells, were determined using flow cytometry, while inflammatory markers associated with tumor progression were evaluated using RT-qPCR. The CD73 blockade by NE-siRNA CD73 was found to induce tumor cell apoptosis. Meanwhile, the population of Tregs, microglia, and macrophages was significantly reduced in the tumor microenvironment, though IL-6, CCL17, and CCL22 increased. The treatment selectively decreased CD73 expression in the GB cells as well as in the tumor-associated-macrophages/microglia. This study indicates that CD73 knockdown using a nanotechnological approach to perform nasal delivery of siRNA-CD73 to CNS can potentially regulate the glioblastoma immune microenvironment and delay tumor growth by inducing apoptosis.Keywords
Funding Information
- Conselho Nacional de Desenvolvimento Científico e Tecnológico (422298/2016-6, 310846/2014-5)
- Coordenação de Aperfeiçoamento de Pessoal de Nível Superior
- Fundação de Amparo à Pesquisa do Estado do Rio Grande do Sul (16/2551-0000265-7, 16/2551-0000473-0)
This publication has 40 references indexed in Scilit:
- Serum macrophage-derived chemokine/CCL22 levels are associated with glioma risk, CD4 T cell lymphopenia and survival timeInternational Journal of Cancer, 2015
- Increased proportion of FoxP3+ regulatory T cells in tumor infiltrating lymphocytes is associated with tumor recurrence and reduced survival in patients with glioblastomaCancer Immunology, Immunotherapy, 2015
- Nucleotide receptors control IL-8/CXCL8 and MCP-1/CCL2 secretions as well as proliferation in human glioma cellsBiochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 2015
- The epidemiology of glioma in adults: a "state of the science" reviewNeuro-Oncology, 2014
- Involvement of ecto-5′-nucleotidase/CD73 in U138MG glioma cell adhesionMolecular and Cellular Biochemistry, 2011
- IL-6 promotion of glioblastoma cell invasion and angiogenesis in U251 and T98G cell linesJournal of Neuro-Oncology, 2010
- Generation and Accumulation of Immunosuppressive Adenosine by Human CD4+CD25highFOXP3+ Regulatory T CellsJournal of Biological Chemistry, 2010
- The role of ecto-5′-nucleotidase/CD73 in glioma cell line proliferationMolecular and Cellular Biochemistry, 2008
- The role of human glioma-infiltrating microglia/macrophages in mediating antitumor immune responses1Neuro-Oncology, 2006
- Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT MethodMethods, 2001